Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09XZL
|
|||
| Former ID |
DIB009839
|
|||
| Drug Name |
LX-7101
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Phase 1/2 | [1] | |
| Company |
Lexicon Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H29N7O3
|
|||
| Canonical SMILES |
CC1=CNC2=C1C(=NC=N2)N3CCC(CC3)(CN)C(=O)NC4=CC(=CC=C4)OC(=O)N(C)C
|
|||
| InChI |
1S/C23H29N7O3/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27)
|
|||
| InChIKey |
PWPNYABQEOGNNC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1192189-69-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein kinase (PK) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01528111) Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension. U.S. National Institutes of Health. | |||
| REF 2 | Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.